Recent News

• 04.24.2025 - Kairos Pharma Ltd. Provides Letter to Stockholders
• 04.17.2025 - Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
• 03.31.2025 - Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
• 03.27.2025 - Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
• 03.20.2025 - Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
• 02.26.2025 - Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
• 02.18.2025 - Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
• 02.11.2025 - Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
• 02.06.2025 - Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma

Recent Filings

• 04.22.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 04.15.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
• 03.20.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 8-K Current report
• 02.26.2025 - EX-99.1 EX-99.1
• 02.26.2025 - 8-K Current report
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities